HUTCHMED (China) Limited (HCM)
Market Cap | 3.00B |
Revenue (ttm) | 838.00M |
Net Income (ttm) | 100.78M |
Shares Out | 174.27M |
EPS (ttm) | 0.60 |
PE Ratio | 28.76 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 65,262 |
Open | 17.34 |
Previous Close | 17.56 |
Day's Range | 17.17 - 17.34 |
52-Week Range | 11.70 - 21.92 |
Beta | 0.65 |
Analysts | Buy |
Price Target | 29.70 (+72.47%) |
Earnings Date | Jul 29, 2024 |
About HCM
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, an... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for HCM stock is "Buy." The 12-month stock price forecast is $29.7, which is an increase of 72.47% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/0/p/conf10-2496750.jpg)
HUTCHMED to Announce 2024 Half-Year Financial Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six mon...
![](https://cdn.snapi.dev/images/v1/y/t/conf4-2492266.jpg)
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — — HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 —
![](https://cdn.snapi.dev/images/v1/1/6/press8-2490894.jpg)
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial —
![](https://cdn.snapi.dev/images/v1/a/a/press12-2481240.jpg)
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior...
![](https://cdn.snapi.dev/images/v1/8/v/press10-2467549.jpg)
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical ...
![](https://cdn.snapi.dev/images/v1/s/v/press17-2458206.jpg)
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024
![](https://cdn.snapi.dev/images/v1/4/b/press17-2446712.jpg)
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from se...
![](https://cdn.snapi.dev/images/v1/g/r/press19-2437148.jpg)
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-
![](https://cdn.snapi.dev/images/v1/d/w/press2-2436401.jpg)
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ...
![](https://cdn.snapi.dev/images/v1/w/r/press16-2428462.jpg)
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED's surufat...
![](https://cdn.snapi.dev/images/v1/d/8/press17-2428463.jpg)
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrat...
![](https://cdn.snapi.dev/images/v1/c/l/press13-2417232.jpg)
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bh...
![](https://cdn.snapi.dev/images/v1/h/b/press4-2394062.jpg)
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
![](https://cdn.snapi.dev/images/v1/s/4/press3-2358004.jpg)
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from ...
![](https://cdn.snapi.dev/images/v1/p/r/press8-2351931.jpg)
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
ROCKVILLE, Md. and SUZHOU, China , April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial...
![](https://cdn.snapi.dev/images/v1/a/j/press20-2351212.jpg)
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 —
![](https://cdn.snapi.dev/images/v1/6/c/press9-2345288.jpg)
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —
![](https://cdn.snapi.dev/images/v1/c/q/press6-2336697.jpg)
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the regis...
![](https://cdn.snapi.dev/images/v1/s/g/press3-2297938.jpg)
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA r...
![](https://cdn.snapi.dev/images/v1/r/r/press11-2263481.jpg)
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHM...
![](https://cdn.snapi.dev/images/v1/9/2/press20-2257173.jpg)
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceutic...
![](https://cdn.snapi.dev/images/v1/m/p/conf19-2254709.jpg)
HUTCHMED to Announce 2023 Final Results
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the ye...
![](https://cdn.snapi.dev/images/v1/4/b/press7-2249993.jpg)
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong —
![](https://cdn.snapi.dev/images/v1/h/x/press1-2224976.jpg)
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —
![](https://cdn.snapi.dev/images/v1/s/l/press15-2193970.jpg)
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that under the 2023 simple ren...